Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedApr 15, 2025
DataAggregated Company Financials
Companies5
  • 7D7.0%
  • 3M-11.4%
  • 1Y47.0%
  • YTD-10.9%

Last week, the Biotech industry hasn't moved much but Idorsia is up 6.3% in that time. The past year has been better, since the industry has gained 38% in that time. As for the next few years, earnings are forecast to decline by 9.5% per annum.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 15 Apr 2025CHF 1.5bCHF 411.1mCHF 65.6m4.6x23.4x3.7x
Thu, 13 Mar 2025CHF 1.7bCHF 409.3m-CHF 35,110,868.005.1x-47.7x4.1x
Sat, 08 Feb 2025CHF 1.9bCHF 330.3m-CHF 75,131,868.003.3x-26x5.9x
Mon, 06 Jan 2025CHF 1.7bCHF 330.3m-CHF 75,131,868.002.8x-22.8x5.2x
Wed, 04 Dec 2024CHF 1.6bCHF 330.9m-CHF 87,805,465.001.6x-18.1x4.8x
Fri, 01 Nov 2024CHF 1.9bCHF 333.1m-CHF 82,023,629.001.7x-22.9x5.6x
Sun, 29 Sep 2024CHF 1.6bCHF 333.6m-CHF 81,088,264.001.7x-19.1x4.6x
Tue, 27 Aug 2024CHF 1.4bCHF 319.7m-CHF 142,008,264.001.9x-9.9x4.4x
Thu, 25 Jul 2024CHF 745.2mCHF 151.7m-CHF 146,197,264.001.5x-5.1x4.9x
Sat, 22 Jun 2024CHF 831.7mCHF 151.7m-CHF 146,197,264.001.6x-5.7x5.5x
Mon, 20 May 2024CHF 538.2mCHF 170.3m-CHF 131,508,021.161x-4.1x3.2x
Wed, 17 Apr 2024CHF 443.1mCHF 67.6m-CHF 173,109,973.720.09x-2.6x6.6x
Fri, 15 Mar 2024CHF 352.8mCHF 68.7m-CHF 170,990,979.240.3x-2.1x5.1x
Sun, 11 Feb 2024CHF 370.7mCHF 55.4m-CHF 173,281,198.021x-2.1x6.7x
Tue, 09 Jan 2024CHF 339.1mCHF 317.3m-CHF 176,125,693.000.6x-1.9x1.1x
Thu, 07 Dec 2023CHF 382.7mCHF 317.8m-CHF 208,951,081.00n/a-1.8x1.2x
Sat, 04 Nov 2023CHF 280.5mCHF 318.4m-CHF 211,153,359.00n/a-1.3x0.9x
Mon, 02 Oct 2023CHF 262.4mCHF 318.6m-CHF 213,557,748.00n/a-1.2x0.8x
Wed, 30 Aug 2023CHF 303.0mCHF 318.5m-CHF 188,561,655.00n/a-1.6x1x
Fri, 28 Jul 2023CHF 339.6mCHF 320.2m-CHF 179,536,194.00n/a-1.9x1.1x
Sun, 25 Jun 2023CHF 310.6mCHF 331.2m-CHF 180,840,246.00n/a-1.7x0.9x
Tue, 23 May 2023CHF 335.3mCHF 329.8m-CHF 183,165,729.00n/a-1.8x1x
Thu, 20 Apr 2023CHF 432.9mCHF 482.1mCHF 8.2m1.6x52.9x0.9x
Sat, 18 Mar 2023CHF 438.5mCHF 497.1mCHF 11.5m1.5x38x0.9x
Mon, 13 Feb 2023CHF 483.0mCHF 493.4mCHF 14.5m1.7x33.3x1x
Wed, 11 Jan 2023CHF 518.4mCHF 493.4mCHF 14.5m1.7x35.8x1.1x
Fri, 09 Dec 2022CHF 513.4mCHF 493.4mCHF 14.5m1.8x35.4x1x
Sun, 06 Nov 2022CHF 511.8mCHF 509.0mCHF 14.9m1.8x34.4x1x
Tue, 04 Oct 2022CHF 549.1mCHF 508.4mCHF 15.9m2.1x34.6x1.1x
Thu, 01 Sep 2022CHF 529.3mCHF 499.3mCHF 36.7m1.7x14.4x1.1x
Sat, 30 Jul 2022CHF 526.1mCHF 483.8mCHF 42.3m1.9x12.4x1.1x
Mon, 27 Jun 2022CHF 540.7mCHF 454.1mCHF 80.7m2.1x6.7x1.2x
Wed, 25 May 2022CHF 699.0mCHF 467.2mCHF 24.6m2x28.5x1.5x
Fri, 22 Apr 2022CHF 1.0bCHF 293.6m-CHF 142,281,938.002x-7.1x3.4x
Price to Earnings Ratio

-7.1x


Total Market Cap: CHF 1.0bTotal Earnings: -CHF 142,281,938.00Total Revenue: CHF 293.6mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average 1.9x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 22.1x which is higher than its 3-year average PE of 1.8x.
  • The 3-year average PS ratio of 2.7x is lower than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 12% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market4.14%
Healthcare3.18%
Biotech6.96%
Biotech6.96%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KURN Kuros BiosciencesCHF 22.1623.3%
+CHF 159.1m		202.7%PS11.1x
IDIA IdorsiaCHF 1.1114.8%
+CHF 32.1m		-48.5%PS2.2x
SANN Santhera Pharmaceuticals HoldingCHF 13.966.1%
+CHF 10.1m		53.6%PE2.8x
BSLN Basilea PharmaceuticaCHF 41.702.0%
+CHF 9.7m		1.5%PE6.5x
RLF Relief Therapeutics HoldingCHF 2.4720.2%
+CHF 5.2m		96.0%PS3.7x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

RLF

CHF 2.47

Relief Therapeutics Holding

7D

20.2%

1Y

96.0%

BSLN

CHF 41.70

Basilea Pharmaceutica

7D

2.0%

1Y

1.5%

Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Apr 10
Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

SANN

CHF 13.96

Santhera Pharmaceuticals Holding

7D

6.1%

1Y

53.6%

KURN

CHF 22.16

Kuros Biosciences

7D

23.3%

1Y

202.7%

MOLN

CHF 3.25

Molecular Partners

7D

1.2%

1Y

-3.8%

IDIA

CHF 1.11

Idorsia

7D

14.8%

1Y

-48.5%